GlassScriptPhysician profile
Liji George
NPI 1467659292
$7,922.32
in general payments reported to CMS, 2019-2025
31 companies · $1,425 in 2025
The $1,425 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $1,381 · 2021: $761 · 2022: $338 · 2023: $1,406 · 2024: $1,409 · 2025: $1,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,239.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,747.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,389.26 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,360.95 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $726.67 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $367.08 | 2023-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $325.32 | 2019-2021 | |
| Pfizer INC. | $290.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $283.37 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $186.93 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $173.19 | 2019-2024 | |
| Dynavax Technologies Corporation | $148.81 | 2023-2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $140.66 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $119.56 | 2019-2021 | |
| Dexcom, INC. | $94.59 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $85.75 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $84.75 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Daiichi Sankyo INC. | $75.21 | 2020-2022 | |
| Abbvie INC. | $48.20 | 2022-2024 | |
| Abbott Laboratories | $47.83 | 2021-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $29.79 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $23.26 | 2024 | Keveyis |
| Allergan, INC. | $23.18 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.37 | 2019 | |
| Shire North American Group INC | $19.33 | 2019 | |
| Eisai INC. | $18.17 | 2020 | |
| Si-Bone, INC. | $17.33 | 2024 | |
| Bausch Health US, LLC | $16.80 | 2020 | |
| Gilead Sciences, INC. | $16.45 | 2020 | |
| Phadia US INC. | $15.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.87 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liji George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.